Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 10OTHER 8NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1Ganglioneuroblastoma 1

Interventions

Specimen Handling 68Magnetic Resonance Spectroscopy 53Cyclophosphamide 45Vincristine 37Cisplatin 31Radiotherapy 30Radiation 30Carboplatin 29Dexamethasone 28Etoposide 26Biopsy 26Doxorubicin 24daratumumab 18Prednisone 18Radiotherapy, Intensity-Modulated 17durvalumab 16Platinum 16Irinotecan 16Cytarabine 16Paclitaxel 15Gemcitabine 151,2-diaminocyclohexaneplatinum II citrate 15Observation 14Methotrexate 14Leucovorin 14Docetaxel 14Lenalidomide 13X-Rays 12Watchful Waiting 12Radiotherapy, Conformal 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × lorlatinib × 1 year × Clear all
NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡